Back to results
US 2022/0177479 A1Published application
Novel substituted xanthine derivatives
AssigneesBoehringer Ingelheim International GmbH, Hydra Biosciences, Inc.
InventorKai Gerlach
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of formula I a process for their manufacture, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels. R1, R2, R3, R4 and R5 have meanings given in the description.
Claims18
A compound of formula I
- in which
- R1 represents ethyl, isopropyl, isobutyl, cyclobutyl;
- R2 represents
- R3 represents hydrogen, fluoro, C1-C3-alkyl optionally substituted with one or more fluorine atoms;
- R4 represents hydrogen or fluoro;
- R5 represents
- which groups are optionally substituted with one or more fluorine atoms and/or one or more C1-C3-alkyl fluorinated with one or more fluorine atoms.
4 more elements
(canceled)
(canceled)
(canceled)
A method for treating a TRPC5 mediated disorder in a subject, the method comprising administering to the subject an effective amount of a pharmaceutically acceptable salt of the compound according to formula (I):
- in which
- R1 represents ethyl, isopropyl, isobutyl, cyclobutyl;
- R2 represents
- R3 represents hydrogen, fluoro, C1-C3-alkyl optionally substituted with one or more fluorine atoms;
- R4 represents hydrogen or fluoro;
- R5 represents
- which groups are optionally substituted with one or more fluorine atoms and/or one or more C1-C3-alkyl fluorinated with one or more fluorine atoms.
4 more elements
Dependencies are inferred from the claim text.